Fig. 2

FBX treatment confers resistance to mitochondrial inhibitors in N2 worms. A Metabolic pathways of purine nucleotides and active sites of FBX. B Schematic diagram of the mitochondrial electron transport chain and the active site of a mitochondrial inhibitor, NaN₃. C The mitochondrial inhibitor NaN₃ (500 µM) and FBX (0, 5, 10, 20, and 40 µg/ml) were added to wild-type nematodes (N2) at the L4 stage, and the survival time was measured. Log-rank P value: FBX 0 µg/ml vs FBX 5 µg/ml = 0.0117. Log-rank P value: FBX 0 µg/ml vs FBX 10 µg/ml = 0.0406. Survival rates of 37% at FBX (0, 5, 10, 20 and 40 µg/ml)-treated animals: 13.68, 13.77, 15.38, 13.24, and 14.01 h, respectively. Number of trials: FBX 0 µg/ml, 8 times; FBX 5 µg/ml, 3 times; FBX 10 µg/ml, 3 times; FBX 20 µg/ml, 4 times; FBX 40 µg/ml, 4 times. Total number of FBX (0, 5, 10, 20, and 40 µg/ml)-treated animals: 200, 49, 43, 106, and 108, respectively. NS, not significant. D NaN₃ (500 µM) and FBX (0, 5, 10, 20, and 40 µg/ml) were added to the hprt-1 mutant (tm6318) nematodes in the L4 stage, and survival times were measured. Log-rank P value: not significant. Survival rates of 37% at FBX (0, 5, 10, 20, and 40 µg/ml)-treated animals: day 6.71, 7.38, 7.70, 8.04 and 6.43, respectively. Number of trials: FBX 0 µg/ml, 4 times; FBX 5 µg/ml, 3 times; FBX 10 µg/ml, 3 times; FBX 20 µg/ml, 3 times; FBX 40 µg/ml, 3 times. Total number of FBX (0, 5, 10, 20, and 40 µg/ml)-treated animals: 102, 60, 55, 59, and 60, respectively. E NaN₃ (500 µM) and FBX (0, 5, 10, 20, and 40 µg/ml) were added to the L4 stage of the xdh-1 mutant (tm9911) nematodes, and survival time was measured. Log-rank P value: not significant. Survival rates of 37% at FBX (0, 5, 10, 20, and 40 µg/ml)-treated animals: 7.51, 8.85, 8.23, 7.46, and 6.26 h, respectively. Number of trials: FBX 0 µg/ml, 10 times; FBX 5 µg/ml, 3 times; FBX 10 µg/ml, 4 times; FBX 20 µg/ml, 3 times; FBX 40 µg/ml, 4 times. Total number of FBX (0, 5, 10, 20, and 40 µg/ml)-treated animals: 225, 79, 80, 74, and 77, respectively.